Minichillo, Santino; Pantaleo, Maria Abbondanza; Nannini, Margherita; Coccolo, Fabio; Gatto, Lidia; Biasco, Guido; Brandi, Giovanni, Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma, «BMC RESEARCH NOTES», 2015, 8, Article number: 325, pp. 1 - 4 [articolo]Open Access
Brandi, Giovanni, Follow-up in oncologia, Bologna, Bononia, 2015, pp. 368 . [libro]
Brandi, G; De Lorenzo, S; Di Girolamo, S; Bellentani, S; Saccoccio, G; Biasco G, Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib., «TUMORI», 2015, 101(2), pp. 46 - 48 [articolo]
Brandi, Giovanni; Farioli, Andrea; Astolfi, Annalisa; Biasco, Guido; Tavolari, Simona, Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies, «ONCOTARGET», 2015, 6, pp. 14744 - 14753 [articolo]Open Access
I. Garajová; G. Brandi; G. Biasco; [..]; E. Giovannetti, L27MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas, in: Annals of Oncology, 2015(atti di: x, x, x) [atti di convegno-poster]
Saponara, Maristella; Urbini, Milena; Astolfi, Annalisa; Indio, Valentina; Ercolani, Giorgio; Del Gaudio, Massimo; Santini, Donatella; Pirini, Maria Giulia; Fiorentino, Michelangelo; Nannini, Margherita; Lolli, Cristian; Mandrioli, Anna; Gatto, Lidia; Brandi, Giovanni; Biasco, Guido; Pinna, Antonio Daniele; Pantaleo, Maria Abbondanza, Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS), «ONCOTARGET», 2015, 6, pp. 42243 - 42257 [articolo]
Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M; REACH Trial Investigators; Brandi G., Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial, «THE LANCET ONCOLOGY», 2015, 16, pp. 859 - 870 [articolo]
Farioli, Andrea; Brandi, Giovanni, Risk Factors of Cholangiocarcinoma, in: Cholangiocarcinoma, New York, Nova Science Publishers, Inc., 2015, pp. 39 - 52 [capitolo di libro]
Fornaro, Lorenzo; Vivaldi, Caterina; Cereda, Stefano; Leone, Francesco; Aprile, Giuseppe; Lonardi, Sara; Silvestris, Nicola; Santini, Daniele; Milella, Michele; Caparello, Chiara; Musettini, Gianna; Pasquini, Giulia; Falcone, Alfredo; Brandi, Giovanni; Sperduti, Isabella; Vasile, Enrico, Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data, «JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH», 2015, 34, pp. 156 - 162 [articolo]
Astolfi, Annalisa; Urbini, Milena; Indio, Valentina; Nannini, Margherita; Genovese, Chiara Giusy; Santini, Donatella; Saponara, Maristella; Mandrioli, Anna; Ercolani, Giorgio; Brandi, Giovanni; Biasco, Guido; Pantaleo, Maria A, Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST), «BMC GENOMICS», 2015, 16, Article number: 892, pp. 1 - 11 [articolo]Open Access
Garajová, I.; Brandi, G.; Biasco, G.; Deserti, M.; Tavolari, S.; Palloni, A.; Verlicchi, L.; Le Large, T.; Giovannetti, E., 219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy, in: European Journal of Cancer, «EUROPEAN JOURNAL OF CANCER», 2015, 51(atti di: ESMO, Wien, 2015) [atti di convegno-poster]
Brandi G;Tavolari S;Guarnieri T;Di Marco M;Paterini P;Macchini M;Di Girolamo S;Papi A;De Rosa F;Biasco G, Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study., «PANCREAS», 2014, 43, pp. 53 - 63 [articolo]
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G., Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects., «CUTANEOUS AND OCULAR TOXICOLOGY», 2014, 33, pp. 1 - 6 [articolo]
M. A. Pantaleo;A. Astolfi;M. Urbini;F. Fuligni;M. Saponara;M. Nannini;C. Lolli;V. Indio;D. Santini;G. Ercolani;G. Brandi;A. D. Pinna;G. Biasco, Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors., «CLINICAL SARCOMA RESEARCH», 2014, 4, pp. 4 - 9 [articolo]
Margherita Nannini;Annalisa Astolfi;Milena Urbini;Valentina Indio;Donatella Santini;Michael C Heinrich;Christopher L Corless;Claudio Ceccarelli;Maristella Saponara;Anna Mandrioli;Cristian Lolli;Giorgio Ercolani;Giovanni Brandi;Guido Biasco;Maria A Pantaleo, Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST), «BMC CANCER», 2014, 14, Article number: 685, pp. 1 - 12 [articolo]Open Access
